Reduced-dose carmustine (300 mg/m2) and melphalan as a conditioning regimen in multiple myeloma patients with CNS involvement: A case series

被引：0
|
作者：
Rueda, Garrett [1 ]
Smith, Eric [2 ]
De Padova, Nicolas [2 ]
Heers, Hayley [2 ]
Komerdelj, Ivan [2 ]
机构：
[1] Banner MD Anderson Canc Ctr, PGY2 Oncol Pharm Resident, 2946 E Banner Gateway Dr, Gilbert, AZ 85234 USA
[2] Banner MD Anderson Canc Ctr, Clin Oncol Pharmacist Malignant Hematol, 2946 E Banner Gateway Dr, Gilbert, AZ 85234 USA
来源：
CURRENT PROBLEMS IN CANCER: CASE REPORTS | 2023年 / 12卷
关键词：
Multiple myeloma; CNS involvement; Carmustine; Autologous stem cell transplant; Conditioning chemotherapy; LONG-TERM OUTCOMES; AUTOLOGOUS TRANSPLANTATION; CELL TRANSPLANTATION; TRIAL;
D O I：
10.1016/j.cpccr.2023.100270
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Single-agent melphalan remains the gold standard for conditioning chemotherapy prior to autologous stem cell transplantation (ASCT) in the multiple myeloma (MM) setting. Melphalan's distribution in the central nervous system (CNS) is limited which raises the question if single-agent melphalan is the ideal conditioning regimen for MM patients with extramedullary involvement in the CNS. Here we present two patients with MM and CNS involvement at baseline who safely received reduced-dose carmustine (300 mg/m2) and melphalan for conditioning chemotherapy prior to ASCT. While this combination has been studied previously, no studies to our knowledge added carmustine to the preparative regimen explicitly for additive CNS penetration in patients with CNS involvement.
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Single centre experience of efficacy and toxicity of reduced-dose melphalan conditioning (140 mg/m2 or 110 mg/m2) in autologous stem cell transplantation for multiple myeloma
    Troy-Barnes, E.
    Melotti, D.
    Camilleri, M.
    Horder, J.
    Newrick, F.
    Marfil, J.
    Lee, L.
    Mahmood, A. S.
    Wisniowski, B.
    Papanikolaou, X.
    Wechalekar, A.
    Sive, J.
    Popat, R.
    Yong, K.
    Rabin, N.
    Kyriakou, C.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 178 - 179
  • [2] Selinexor in Combination with Standard or Reduced-Dose Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Multiple Myeloma
    Shuai, Su
    Xu, Bin
    Li, Chunrui
    Wang, Di
    Tong, Xiwen
    Zhu, Yi
    Mao, Xia
    Xiao, Min
    Zhang, Donghua
    BLOOD, 2024, 144 : 7062 - 7063
  • [3] Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation
    R L Comenzo
    H Hassoun
    T Kewalramani
    V Klimek
    M Dhodapkar
    L Reich
    J Teruya-Feldstein
    M Fleisher
    D Filippa
    S D Nimer
    Leukemia, 2006, 20 : 345 - 349
  • [4] A Lower Dose of Melphalan (140 mg/m2) As Preparative Regimen for Multiple Myeloma in Patients >65 or with Renal Dysfunction
    Saunders, Ila Maewal
    Gulbis, Alison
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2014, 20 (02) : S293 - S294
  • [5] A Lower Dose Of Melphalan (140 mg/m2) As Preparative Regimen For Multiple Myeloma In Patients >65 Or With Renal Dysfunction
    Saunders, Ila Maewal
    Gulbis, Alison M.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BLOOD, 2013, 122 (21)
  • [6] Double Transplantation with Melphalan (200 mg/m2) Compared with Triple Transplantation with Intermediate Dose Melphalan (100 mg/m2) in Patients with Multiple Myeloma
    Ludwig, Heinz
    Spicka, Ivan
    Linkesch, Werner
    Greil, Richard
    Kasparu, Hedwig
    Gunsilius, Eberhard
    Thaler, Josef
    Drach, Johannes
    Kuhn, Ingrid
    Weissmann, Adalbert
    Hinke, Axel
    BLOOD, 2008, 112 (11) : 1139 - 1139
  • [7] Reduced-dose melphalan (140 or 100 mg/m2) maintains efficacy and tolerability for multiple myeloma patients with advanced age or renal impairment undergoing autologous transplant
    Krem, Maxwell
    Phuong Ngo
    Reynolds, Samuel
    Quang Nguyen
    Jayswal, Rani
    Weiss, Heidi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E294 - E295
  • [8] Dose-intensive melphalan regimens (100 mg/m2 versus 200 mg/m2) in multiple myeloma patients.
    Boccadoro, M
    Bringhen, S
    Cavallo, F
    Falco, P
    Bertola, A
    Barbui, A
    Caravita, T
    Musto, P
    Pescosta, N
    Vignetti, M
    Palumbo, A
    BLOOD, 2002, 100 (11) : 431A - 431A
  • [9] Results of a phase I/II trial adding carmustine (300mg/m2) to melphalan (200mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation
    Comenzo, RL
    Hassoun, H
    Kewalramani, T
    Klimek, V
    Dhodapkar, M
    Reich, L
    Teruya-Feldstein, J
    Fleisher, M
    Filippa, D
    Nimer, SD
    LEUKEMIA, 2006, 20 (02) : 345 - 349
  • [10] Reduced-Dose Melphalan (140 or 100 mg/m2) Maintains Efficacy and Tolerability for Multiple Myeloma Patients with Advanced Age or Renal Impairment Undergoing Auto-HCT
    Ngo, Phuong T.
    Reynolds, Samuel B.
    Nguyen, Quang L.
    Jayswal, Rani
    Weiss, Heidi L.
    Krem, Maxwell M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
12345